Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
|Articles|January 22, 2008
MedSurge Advances to show new technologies at AAD
Dallas, Texas - MedSurge Advances in a partnership with French laser manufacturers, Quantel Derma and Osyris, will exhibit new technologies during the American Academy of Dermatology (AAD) Meeting in San Antonio.
Advertisement
Dallas, Texas
- MedSurge Advances in a partnership with French laser manufacturers, Quantel Derma and Osyris, will exhibit new technologies Feb. 2-5 during the American Academy of Dermatology (AAD) Meeting in San Antonio, Texas at the Henry B. Gonzalez Convention Center, according to PRWeb.
Equipment to be exhibited include the Prolite III, a multi-handpiece Intense Pulsed Light (IPL) system, the 308 nm handheld excimer device, used for the treatment of psoriasis and vitiligo, the EXEL02 CO2 Fraxel laser, the Pharaon Lipo and Pharaon Exo, both laser lipolysis devices used to reduce fat deposits and treat vascular conditions, respectively.
Advertisement
Related to this article
Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
2
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
3
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
4
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
5